Login to Your Account

Financings Roundup

Thursday, December 8, 2011
• Lpath Inc., of San Diego, filed to raise up to $10 million through a public offering of stock and warrants. Terms have not yet been set. Lpath trades on the OTCQB. Proceeds would be used for general corporate purposes, including a Phase II trial of iSONEP for wet age-related macular degeneration and a Phase Ib trial of the drug for retinal pigment epithelium detachment. ISONEP is an antibody targeting the bioactive lipid sphingosine-1-phosphate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription